137 related articles for article (PubMed ID: 38804898)
21. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
Kalauz A; Tiringer KV; Horváth V; Kapui I
J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
[TBL] [Abstract][Full Text] [Related]
22. Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications.
Li K; Ricker K; Tsai FC; Hsieh CJ; Osborne G; Sun M; Marder ME; Elmore S; Schmitz R; Sandy MS
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574388
[TBL] [Abstract][Full Text] [Related]
23. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
Charoo NA; Dharani S; Khan MA; Rahman Z
AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
[TBL] [Abstract][Full Text] [Related]
24. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
Sharma N; Patel R; Bothara T; Jain S; Shah RP
J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
[TBL] [Abstract][Full Text] [Related]
25. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
26. Carcinogenicity of the isomeric, N-nitroso-delta3-and N-nitroso-delta2-piperidines in rats and the in vivo isomerization of the delta3-to the delta2-isomer.
Kupper R; Reuber MD; Blackwell BN; Lijinsky W; Koepke SR; Michejda CJ
Carcinogenesis; 1980 Sep; 1(9):753-7. PubMed ID: 11219865
[TBL] [Abstract][Full Text] [Related]
27. Mutational specificities of N-nitrosamines in a host-mediated assay: comparison with direct-acting N-nitroso compounds in vitro and an approach to deducing the nature of ultimate mutagens in vivo.
Liu YX; Guttenplan JB
Mol Carcinog; 1992; 6(4):232-7. PubMed ID: 1485914
[TBL] [Abstract][Full Text] [Related]
28. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans.
Hoffmann D; Brunnemann KD; Prokopczyk B; Djordjevic MV
J Toxicol Environ Health; 1994 Jan; 41(1):1-52. PubMed ID: 8277523
[TBL] [Abstract][Full Text] [Related]
29. PERIOCULAR HIGH RISK BCCS AFTER ADDITIONAL/PARALLEL INTAKE OF TORASEMIDE, MOXONIDINE AND MIRABEGRON: IMPORTANT LINKS TO SKIN CANCER RELATED (PHOTO-) NITROSOGENESIS IN THE CONTEXT OF PHARMACO-ONCOGENESIS.
Tchernev G; Dimova D
Georgian Med News; 2024 Feb; (347):70-76. PubMed ID: 38609117
[TBL] [Abstract][Full Text] [Related]
30. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
Dos Santos CEM; Dorta DJ; de Oliveira DP
Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
[TBL] [Abstract][Full Text] [Related]
31. EDUCATION FROM DERMATOLOGISTS: THE SIMULTANEOUSLY DEVELOPMENT OF 16 KERATINOCYTIC CANCERS AFTER USE OF METFORMIN IN COMBINATION WITH LOSARTAN/ HYDROCHLOROTHIAZIDE, METOPROLOL AND NIFEDIPINE- IMPORTANT LINKS TO DRUG RELATED (PHOTO)-NITROSO-CARCINOGENESIS AND ONCOPHARMACOGENESIS.
Tchernev G; Dimova D
Georgian Med News; 2024 Feb; (347):136-141. PubMed ID: 38609130
[TBL] [Abstract][Full Text] [Related]
32. [Quantitative structure-activity relationship prediction of carcinogenicity of N-nitroso compounds based on category approach and read-across].
Liang QQ; Zheng WW; He GS; Qu WD
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):621-627. PubMed ID: 28693087
[No Abstract] [Full Text] [Related]
33. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
Thomas R; Thresher A; Ponting DJ
Regul Toxicol Pharmacol; 2021 Apr; 121():104875. PubMed ID: 33556416
[TBL] [Abstract][Full Text] [Related]
34. Developing Structure-Activity Relationships for
Cross KP; Ponting DJ
Comput Toxicol; 2021 Nov; 20():. PubMed ID: 34901581
[TBL] [Abstract][Full Text] [Related]
35. Computational evidence for α-nitrosamino radical as initial metabolite for both the P450 dealkylation and denitrosation of carcinogenic nitrosamines.
Ji L; Schüürmann G
J Phys Chem B; 2012 Jan; 116(2):903-12. PubMed ID: 22136655
[TBL] [Abstract][Full Text] [Related]
36. Permitted daily exposure limits for noteworthy N-nitrosamines.
Johnson GE; Dobo K; Gollapudi B; Harvey J; Kenny J; Kenyon M; Lynch A; Minocherhomji S; Nicolette J; Thybaud V; Wheeldon R; Zeller A
Environ Mol Mutagen; 2021 Jun; 62(5):293-305. PubMed ID: 34089278
[TBL] [Abstract][Full Text] [Related]
37. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
[TBL] [Abstract][Full Text] [Related]
38. NITROSOGENESIS LESSONS FROM DERMATOLOGISTS-NITROSAMINES/ NDSRIS CONTAMINATION OF THE POLIMEDICATION IN POLIMORBID PATIENTS AS THE MOST POWERFUL SKIN CANCER INDUCTOR: DOUBLE HATCHET FLAP FOR SCC OF THE SCALP OCCURRING DURING TREATMENT WITH VALSARTAN/ HYDROCHLOROTHIAZIDE AND LERCANIDIPINE.
Tchernev G
Georgian Med News; 2023 Sep; (342):74-79. PubMed ID: 37991960
[TBL] [Abstract][Full Text] [Related]
39. DNA adducts from N-nitrosodiethanolamine and related beta-oxidized nitrosamines in vivo: (32)P-postlabeling methods for glyoxal- and O(6)-hydroxyethyldeoxyguanosine adducts.
Loeppky RN; Ye Q; Goelzer P; Chen Y
Chem Res Toxicol; 2002 Apr; 15(4):470-82. PubMed ID: 11952332
[TBL] [Abstract][Full Text] [Related]
40. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
